Shanghai Bozhiyan New Drug Research Co., Ltd.

Primary objective: To study the pharmacokinetic characteristics of the test preparation avatrombopag maleate tablets (specification: 20 mg) and the reference preparation avatrombopag maleate tablets (Doptelet/Su Kexin, specification: 20 mg) in healthy adult subjects, and to evaluate the oral bioequivalence of the two preparations. Secondary objective: To study the safety of the test preparation avatrombopag maleate tablets (specification: 20 mg) and the reference preparation avatrombopag maleate tablets (Doptelet/Su Kexin) (specification: 20 mg) in healthy subjects.

Primary objective: To study the pharmacokinetic characteristics of the test preparation avatrombopag maleate tablets (specification: 20 mg, licensed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., produced by Henan Fusen Pharmaceutical Co., Ltd.) and the reference preparation avatrombopag maleate tablets (Doptelet®/Sukoxin®, specification: 20 mg; licensed by AkaRx Inc., produced by Kawashima Plant, Eisai Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary objective: To study the safety of the test preparation avatrombopag maleate tablets (specification: 20 mg) and the reference preparation avatrombopag maleate tablets (Doptelet®/Sukoxin®) (specification: 20 mg) in healthy subjects.

Main purpose: The pharmacokinetic characteristics of the test preparation ivocate tablets (specification: 1 mg, licensed by Shanghai Bozhi Yanxin Drug Research Co., Ltd., produced by Jiangsu Litai Pharmaceutical Co., Ltd.) and the reference preparation ivocate tablets (Orkedia®, specification: 1 mg; produced by Kyowa Kirin Co., Ltd.) were studied in healthy adult subjects after a single oral dose in fasting and fed states, and the bioequivalence of the two preparations after oral administration in fasting and fed states was evaluated. Secondary Purpose: To investigate the safety of the test preparation, ivocate tablets (strength: 1 mg) and the reference preparation, ivocate tablets (Orkedia®) (strength: 1 mg) in healthy subjects.